(AP) -- In a case that could affect India's role as drug provider to the developing world, the Supreme Court began hearing arguments Tuesday over whether the government had the right to deny a patent to Swiss drugmaker Novartis ...
(AP) -- Gilead Sciences Inc. will allow some of its AIDS drugs to be made by generic manufacturers, potentially increasing their availability in poor countries, particularly in Africa, officials said Tuesday.
US officials sought a "groundbreaking" injunction against Indian drug giant Ranbaxy on Wednesday, saying the maker of the first generic version of cholesterol-lowering Lipitor has failed to meet US safety guidelines.
(AP) -- Efforts by India and the European Union to strengthen trade are threatening India's ability to deliver lifesaving medicines to the world's poorest, analysts say as the two sides push through protracted ...
(AP) -- India effectively ended Bayer's monopoly on a patented cancer drug Monday, licensing a much cheaper generic under a unique law aimed at keeping costs affordable.
More than eight out of every 10 prescriptions dispensed in the US is generic. This growth is due to a large number of top-selling drugs going off patent over the past decade, as well as innovations in t ...
Shares in Indian generic drugs giant Ranbaxy Laboratories crashed by as much as 35 percent on Monday after the US Food and Drug Administration suspended imports from one of its factories.
Manufacturers of generic drugs cannot be sued for adverse side effects caused by products that they did not themselves design, the US Supreme Court ruled on Monday.
India's biggest drugmaker by sales, Ranbaxy Laboratories, has assured shareholders it is taking "stringent steps" to resolve a US ban on imports of medicines made at its newly renovated showcase plant.
U.S. health regulators will require generic versions of the best-selling painkiller OxyContin to include recent formulation changes designed to make the pill harder to abuse.
South Africa's government has published a draft intellectual property policy with potential far-reaching effects for pharmaceutical patents, which rights groups hailed Monday as a move towards lower medicine costs.
(Medical Xpress)—Companies may be misusing the drug patenting system in order to gain control over high-cost drugs in Australia, research from the Melbourne Law School has found.
(AP)—The Supreme Court will decide whether generic drug manufacturers can be held responsible in state courts for possible design defects that are in the brand-name medicine they are copying.
Indian group Sun Pharmaceutical Industries is in talks to buy leading Swedish drugmaker Meda AB in what could result in a $5 billion takeover, the Wall Street Journal reported on Friday.